Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Acellular Animal Vaccine for Bordetella Bronchiseptica-mediated Respiratory Infections (Ref # WFU 08-11)
Wake Forest Innovations USA flag USA
Abstract ID:
The novel BcfA accellular vaccine can efficiently elicit protective immune responses against Bordetella respiratory infections without risking subsequent infection by the vaccine strain and disease, as is the case with commercially available vaccines....
Contact Stephen j. Susalka, phd, clp
Participants
You
Email me a copy of this message

Acellular Animal Vaccine for Bordetella Bronchiseptica-mediated Respiratory Infections


Value Proposition


This novel BcfA accellular vaccine can efficiently elicit protective immune responses without the risk of subsequent infection by the vaccine strain and disease, as is the case with the present commercially available vaccines for Bordetella respiratory infections.


Invention Summary


Inventors in the Microbiology and Immunology Department at Wake Forest School of Medicine have developed an acellular B. bronchiseptica vaccine comprised of the immunogenic BcfA (Bordetella colonization factor A) protein, which with remarkable efficacy establishes protective immunity in vivo against Bordetella infections.
Proof of concept has been established in an in vivo mouse model, and both passive and active immunization have been shown to induce complete protection from bordetellosis, greatly decreased bacterial burden, high antibody titers and markedly reduced pulmonary injury.


Competitive Benefits



Vaccine does not contain whole-cell bacteria, which eliminates the risk of infection by vaccine strain in the host and subsequent disease or zoonosis.
Vaccine is cost-effectively produced by using recombinant DNA techniques.
Vaccine is highly potent and targets multiple animal species of B. bronchiseptica strains.
BcfA protein can be incorporated into a multivalent vaccine, which gives prospects of obtaining greater efficacy and broader protection.


Application Fields



Vaccines for animal and human respiratory disease
Use of serum to prophylactically treat human and animal infections


Stage of Development



Identified and purified the protein
Shown that it is critical for colonization of the mouse trachea
Demonstrated that BcfA anti-serum can provide protection in animals and are in the process to show that this anti-sera can provide protection against B. pertussis infections
Currently testing whether purified BcfA protein provides protection against B. bronchiseptica and B. pertussis in mouse models
It is also planned to test the efficacy of the anti-sera and the purified protein to protect against B. pertussis in non-human primates.


Background



Bordetella bronchiseptica causes respiratory diseases in various animals, such as swine, dogs, cats, sheep, guinea pigs, rabbits, mice and rats.
Commercially available B. bronchiseptica vaccines include live, attenuated, heat-killed, or genetically modified bacteria, all of which are associated with problems such as:
a) persistence of vaccine strain in the host
b) retention of some of the virulence characteristics
c) poor induction of antibody response and protective immunity
The bacterium is also capable of infecting immunocompromised humans, e.g. AIDS and cystic fibrosis patients.


Inventors



Rajendar K. Deora, PhD
Meenu Mishra, PhD
Neelima Sukumar, PhD


Publications


Sukumar N. et al. 2009, Infection and Immunity, 77(2), 885-895

Sukumar et al. 2007, J. Bacteriol. 189:3695-3704


GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought

Exclusive Licensing Arrangement

Possibility of a parallel Sponsored Research Agreement

FEATURED
Last Updated Jan 2014
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
CORPORATION